Scholarlink

Purpose <p>To evaluate the impact of the AirSeal<sup>®</sup> insufflation system on postoperative pain, analgesic consumption, and patient satisfaction following robot-assisted radical prostatectomy (RARP), using real-world patient-reported outcomes (PROMs) collected via a digital health platform.</p> Methods <p>This retrospective multicenter study included 312 patients undergoing RARP for localized prostate cancer across 19 French centers (September 2024–June 2025). Forty-seven patients (15.1%) underwent RARP with AirSeal<sup>®</sup> (low or standard pressure) and 265 (84.9%) with conventional insufflation (standard pressure). Pain scores, measured using the Visual Analogue Scale and analgesic use were recorded daily from postoperative day (POD) 1–14 via the CE-certified Betty Coaching smartphone application. Secondary outcomes included length of stay, sick leave duration, patient satisfaction at 6 weeks, and postoperative complications.</p> Results <p>Baseline characteristics were comparable between groups. Median pain scores were consistently lower with AirSeal<sup>®</sup>, with complete pain resolution by POD8 versus POD14 for conventional insufflation. By POD8, all AirSeal<sup>®</sup> patients were analgesic-free, compared to 83% at POD14 in the control group. All patients were opioid-free within 2 weeks. Hospital stay (median 1&#xa0;day) and satisfaction (median score 10/10) were similar. Complication rates (10.6% vs. 6.8%, <i>p</i> = 0.352) and readmissions did not differ significantly.</p> Conclusion <p>Use of the AirSeal<sup>®</sup> system in RARP was associated with faster pain resolution and earlier cessation of analgesics without compromising perioperative safety. Digital PROMs collection via the Betty Coaching platform offers precise recovery monitoring, reinforcing its role in enhanced recovery pathways and supporting the integration of valveless insufflation technology into minimally invasive urologic surgery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of intra-abdominal pressure with AirSeal® system on patient-reported outcomes and experience measurements after robot-assisted radical prostatectomy

  • 期刊论文

  • 发表日期：

    2025年9月25日

查看全文
  • Bogdan Adrian Buhas,
  • Olivier Skowron,
  • Martin Sié,
  • Stéphane de Vergie,
  • Eric Potiron,
  • Naoufel Miaadi,
  • Gilles Pasticier,
  • Nam-Son Vuong,
  • Laurent Brureau,
  • Christophe Almeras,
  • Vidal Azancot,
  • Jean-Baptiste Beauval,
  • Olivier Belas,
  • Aude De Fourmestraux,
  • Thomas Bommelaere,
  • Nordine Deffar,
  • Gilles Gourtaud,
  • Julien Guillotreau,
  • Truong An Nguyen,
  • Pourya Pashootan,
  • Grégoire Poinas,
  • Arthur Peyrottes,
  • Jean Rouffilange,
  • Mathieu Roumiguié,
  • Philippe Rouvellat,
  • Antoine Van Hove,
  • Caroline Pettenati,
  • Benjamin Pradère,
  • Alexandre de la Taille,
  • Gaëlle Fiard,
  • Charles Dariane,
  • Guillaume Ploussard

摘要

Purpose

To evaluate the impact of the AirSeal® insufflation system on postoperative pain, analgesic consumption, and patient satisfaction following robot-assisted radical prostatectomy (RARP), using real-world patient-reported outcomes (PROMs) collected via a digital health platform.

Methods

This retrospective multicenter study included 312 patients undergoing RARP for localized prostate cancer across 19 French centers (September 2024–June 2025). Forty-seven patients (15.1%) underwent RARP with AirSeal® (low or standard pressure) and 265 (84.9%) with conventional insufflation (standard pressure). Pain scores, measured using the Visual Analogue Scale and analgesic use were recorded daily from postoperative day (POD) 1–14 via the CE-certified Betty Coaching smartphone application. Secondary outcomes included length of stay, sick leave duration, patient satisfaction at 6 weeks, and postoperative complications.

Results

Baseline characteristics were comparable between groups. Median pain scores were consistently lower with AirSeal®, with complete pain resolution by POD8 versus POD14 for conventional insufflation. By POD8, all AirSeal® patients were analgesic-free, compared to 83% at POD14 in the control group. All patients were opioid-free within 2 weeks. Hospital stay (median 1 day) and satisfaction (median score 10/10) were similar. Complication rates (10.6% vs. 6.8%, p = 0.352) and readmissions did not differ significantly.

Conclusion

Use of the AirSeal® system in RARP was associated with faster pain resolution and earlier cessation of analgesics without compromising perioperative safety. Digital PROMs collection via the Betty Coaching platform offers precise recovery monitoring, reinforcing its role in enhanced recovery pathways and supporting the integration of valveless insufflation technology into minimally invasive urologic surgery.